GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » Retained Earnings

SHTDF (Sinopharm Group Co) Retained Earnings : $7,382 Mil (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sinopharm Group Co's retained earnings for the quarter that ended in Dec. 2024 was $7,382 Mil.

Sinopharm Group Co's quarterly retained earnings increased from Dec. 2023 ($6,920 Mil) to Jun. 2024 ($6,947 Mil) and increased from Jun. 2024 ($6,947 Mil) to Dec. 2024 ($7,382 Mil).

Sinopharm Group Co's annual retained earnings increased from Dec. 2022 ($6,155 Mil) to Dec. 2023 ($6,920 Mil) and increased from Dec. 2023 ($6,920 Mil) to Dec. 2024 ($7,382 Mil).


Sinopharm Group Co Retained Earnings Historical Data

The historical data trend for Sinopharm Group Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Retained Earnings Chart

Sinopharm Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6,155.41 6,919.98 7,381.83

Sinopharm Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,155.41 - 6,919.98 6,947.08 7,381.83

Sinopharm Group Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Sinopharm Group Co  (OTCPK:SHTDF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016